This study is currently not recruiting participants.

Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

Study on the Safety and Dosage of an Investigational Medication

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.

Detailed description of study

The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Solid Tumor
  • Age: 18 years - 100 years
  • Gender: All

The purpose of this study is to investigate the safety of an investigational medication in patients. This study aims to find out the best dose to administer to participants.

Participants in this study will receive different doses of the investigational medication. The study will monitor the effects and safety of these dosages.

  • Who can participate: Eligibility criteria are not specified.
  • Study details: Participants will receive varying doses of the investigational medication. The study will observe the effects to determine safety and optimal dosing.
Updated on 19 Feb 2024. Study ID: 1105005289

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team